JPMorgan Chase & Co. cut shares of NeuroPace (NASDAQ:NPCE – Free Report) from an overweight rating to a neutral rating in a research note released on Friday, MarketBeat reports. The brokerage currently has $9.00 target price on the stock, down from their prior target price of $20.00.
NPCE has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. KeyCorp assumed coverage on shares of NeuroPace in a research note on Thursday, September 17th. They issued an “overweight” rating and a $18.00 price objective for the company. Guggenheim restated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. Mizuho assumed coverage on NeuroPace in a report on Thursday, July 23rd. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $15.50.
Check Out Our Latest Stock Analysis on NPCE
NeuroPace Stock Performance
Institutional Trading of NeuroPace
Several institutional investors and hedge funds have recently bought and sold shares of NPCE. BlackRock Inc. purchased a new stake in shares of NeuroPace in the second quarter valued at about $39,369,000. GSA Capital Partners LLP acquired a new stake in shares of NeuroPace during the second quarter worth about $1,836,000. First Light Asset Management LLC grew its holdings in shares of NeuroPace by 16.3% during the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after buying an additional 401,201 shares during the last quarter. Deutsche Bank AG purchased a new position in shares of NeuroPace during the second quarter worth about $14,919,000. Finally, Man Group plc purchased a new position in shares of NeuroPace during the second quarter worth about $1,336,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.
Key NeuroPace News
Here’s some of the latest news about NPCE:
- Positive Sentiment: NeuroPace reported a Q3 loss of $0.03 per share, improved from a $0.11 loss a year earlier and better than analyst estimates. Zacks Q3 earnings report
- Negative Sentiment: Q3 revenue was $23.1 million, below the cited $27.1 million analyst estimate. Revenue from the company’s RNS System grew just 1.4% year over year, signaling limited near-term growth. NeuroPace Q3 results and guidance
- Negative Sentiment: The company cut its 2026 revenue outlook to $91–$92 million, well below the roughly $100.4 million consensus estimate, reinforcing concerns about its sales trajectory. Revenue miss and lowered outlook
About NeuroPace
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
- Five stocks we like better than NeuroPace
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
